Identification
Instrument name
ACACIA PHARMA
Symbol
ACPH
ISIN code
GB00BYWF9Y76
Exchange / Market
Euronext
Trading location
Brussels
Products family
Stocks
Market organization
EuronextBrussels
Capitalization compartment
Compartment B
ICB
Pharmaceuticals
Operation
IPO date
IPO price
EUR 3.60
Issue type
Initial Public offering
Catégorie
IPO
Price range
EUR 3.60 - EUR 4.60

Company profile

Acacia Pharma Group Plc specializes in the research and development of supportive care medicines. The products are intended to support the side effects of anti-cancer treatments (including nausea and vomiting drugs). At the end of 2019, the group had a portfolio of 2 products, including APD403 in phase II of clinical development (treatment of chemically induced nausea and vomiting) and Baremsys in pre-launch phase (treatment of nausea and postoperative vomiting).

Source: Cofisem - Last Update: 03 Apr 2020
Key Executives
Chief Executive Officer Mike Bolinder
Company Secretary Anne-Marie Elsley
Chief Financial Officer Gary Gemignani
Investor Relations Director Gary Gemignani
Source: Cofisem - Last Update: 02 Apr 2020
Key figures
Millenium 2019 2018 2017 2016 2015
Net sales
Income from ordinary activities
Operating income -19,997 -17,611 -3,529 -16,917 -14,603
Cost (net) of financial indebtedness -942 8 22
Equity-accounted companies' contribution to results
Net profit from discontinued activities
Net income -20,394 -18,177 -7,229 -15,810 -15,080
Net income (Group share) -20,394 -18,177 -7,229 -15,810 -15,080
Fiscal year end 12.19 12.18 12.17 12.16 12.15
Length of fiscal year (month) 12 12 12 12 12
Currency & Unit EUR - thousands EUR - thousands EUR - thousands EUR - thousands EUR - thousands
Account Standards
Source: Cofisem - Last Update: 03 Apr 2020
Shareholder information
Gilde Healthcare Partners 26.52 %
Lundbeckfond Invest 19.52 %
Cosmo Pharmaceuticals NV 14.08 %
FMR LLC 7.82 %
AXA Investment Managers 4.15 %
Source: Cofisem - Last Update: 02 Apr 2020